tetano
Editor, Senior Moderator
J Headache Pain
. 2022 Aug 12;23(1):101.
doi: 10.1186/s10194-022-01468-y.
Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case-control study
Rehab Magdy[SUP] 1 [/SUP], Alaa Elmazny[SUP] 1 2 [/SUP], Shaimaa H Soliman[SUP] 3 [/SUP], Eman H Elsebaie[SUP] 4 [/SUP], Sara H Ali[SUP] 5 [/SUP], Ali M Abdel Fattah[SUP] 6 [/SUP], Mahmoud Hassan[SUP] 7 [/SUP], Ahmed Yassien[SUP] 8 [/SUP], Noha A Mahfouz[SUP] 9 [/SUP], Radwa M Elsayed[SUP] 10 [/SUP], Wael Fathy[SUP] 11 [/SUP], Hoda M Abdel-Hamid[SUP] 12 [/SUP], Jehan Mohamed[SUP] 11 [/SUP], Mona Hussein[SUP] 13 [/SUP]
Affiliations
Abstract
Background: The burden of post-coronavirus disease (COVID)-19 symptoms has been increasing and is of great concern in patients with pre-existing chronic medical conditions.This study aimed to delineate the post-COVID-19 neuropsychiatric symptoms among migraine patients compared to the non-migraine control group.
Methods: Two groups, each of 204 COVID-19 survivors, were enrolled in the study after 3 months of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, one group fulfilling the episodic migraine criteria and the other serving as a matching control group. Subjects were evaluated through an in-person interview for post-COVID-19 neuropsychiatric symptoms, including detailed headache patterns and severity, using the visual analogue scale.
Results: The Frequency of headache during the acute phase of COVID-19 was more frequent in migraine patients (OR = 1.60, 95%CI = 1.04-2.45, P-value = 0.031). The reported significant post-COVID-19 neuropsychiatric symptoms in migraine patients compared to controls were fatigue (OR = 1.662, 95%CI = 1.064-2.596, P-value = 0.025), anosmia/hyposmia (OR = 2.06, 95%CI = 1.164- 3.645, P-value = 0.012), cacosmia (OR = 2.663, 95%CI = 1.145-6.195, P-value = 0.019), depression (OR = 2.259, 95%CI = 1.284- 3.975, P-value = 0.004), anxiety (OR = 3.267, 95%CI = 1.747- 6.108, P-value ≤ 0.001), insomnia (OR = 2.203, 95%CI = 1.298- 3.739, P-value = 0.003), and headache (OR = 3.148, 95%CI = 1.616-6.136, P-value = ≤ 0.001).While there was no statistically significant difference between migraine patients and controls regarding the post-COVID-19 functional status score (P-value = 0.102). The pattern of post-COVID-19 headache was reported as chronic headache transformation in 17.6% of the migraine group, with the median intensity rate being 5.5 and IQR (3-7). In the control group, 14% experienced chronic headache attributed to systemic viral infection with a median intensity rate of 2 and IQR (2-5), while 12% experienced a new daily persistent headache with a median intensity of 5 and IQR (1-6).
Conclusion: The study highlighted the importance of follow-up migraine patients upon recovery from COVID-19 infection, being more vulnerable to post-COVID-19 symptoms.
Keywords: Headache; Long COVID-19; Migraine; Neuropsychiatric symptoms; SARS-CoV-2.
. 2022 Aug 12;23(1):101.
doi: 10.1186/s10194-022-01468-y.
Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case-control study
Rehab Magdy[SUP] 1 [/SUP], Alaa Elmazny[SUP] 1 2 [/SUP], Shaimaa H Soliman[SUP] 3 [/SUP], Eman H Elsebaie[SUP] 4 [/SUP], Sara H Ali[SUP] 5 [/SUP], Ali M Abdel Fattah[SUP] 6 [/SUP], Mahmoud Hassan[SUP] 7 [/SUP], Ahmed Yassien[SUP] 8 [/SUP], Noha A Mahfouz[SUP] 9 [/SUP], Radwa M Elsayed[SUP] 10 [/SUP], Wael Fathy[SUP] 11 [/SUP], Hoda M Abdel-Hamid[SUP] 12 [/SUP], Jehan Mohamed[SUP] 11 [/SUP], Mona Hussein[SUP] 13 [/SUP]
Affiliations
- PMID: 35962348
- PMCID: PMC9372973
- DOI: 10.1186/s10194-022-01468-y
Abstract
Background: The burden of post-coronavirus disease (COVID)-19 symptoms has been increasing and is of great concern in patients with pre-existing chronic medical conditions.This study aimed to delineate the post-COVID-19 neuropsychiatric symptoms among migraine patients compared to the non-migraine control group.
Methods: Two groups, each of 204 COVID-19 survivors, were enrolled in the study after 3 months of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, one group fulfilling the episodic migraine criteria and the other serving as a matching control group. Subjects were evaluated through an in-person interview for post-COVID-19 neuropsychiatric symptoms, including detailed headache patterns and severity, using the visual analogue scale.
Results: The Frequency of headache during the acute phase of COVID-19 was more frequent in migraine patients (OR = 1.60, 95%CI = 1.04-2.45, P-value = 0.031). The reported significant post-COVID-19 neuropsychiatric symptoms in migraine patients compared to controls were fatigue (OR = 1.662, 95%CI = 1.064-2.596, P-value = 0.025), anosmia/hyposmia (OR = 2.06, 95%CI = 1.164- 3.645, P-value = 0.012), cacosmia (OR = 2.663, 95%CI = 1.145-6.195, P-value = 0.019), depression (OR = 2.259, 95%CI = 1.284- 3.975, P-value = 0.004), anxiety (OR = 3.267, 95%CI = 1.747- 6.108, P-value ≤ 0.001), insomnia (OR = 2.203, 95%CI = 1.298- 3.739, P-value = 0.003), and headache (OR = 3.148, 95%CI = 1.616-6.136, P-value = ≤ 0.001).While there was no statistically significant difference between migraine patients and controls regarding the post-COVID-19 functional status score (P-value = 0.102). The pattern of post-COVID-19 headache was reported as chronic headache transformation in 17.6% of the migraine group, with the median intensity rate being 5.5 and IQR (3-7). In the control group, 14% experienced chronic headache attributed to systemic viral infection with a median intensity rate of 2 and IQR (2-5), while 12% experienced a new daily persistent headache with a median intensity of 5 and IQR (1-6).
Conclusion: The study highlighted the importance of follow-up migraine patients upon recovery from COVID-19 infection, being more vulnerable to post-COVID-19 symptoms.
Keywords: Headache; Long COVID-19; Migraine; Neuropsychiatric symptoms; SARS-CoV-2.